このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ImpediMed 将来の成長

Future 基準チェック /26

ImpediMed利益と収益がそれぞれ年間49.7%と39.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-11.9% 55.3%なると予測されています。

主要情報

49.7%

収益成長率

55.3%

EPS成長率

Medical Equipment 収益成長	17.0%
収益成長率	39.8%
将来の株主資本利益率	-11.9%
アナリストカバレッジ	Low
最終更新日	01 May 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08

How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Nov 25

業績と収益の成長予測

ASX:IPD - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	32	-2	-1	2	1
6/30/2025	19	-14	-17	-13	2
6/30/2024	11	-21	-23	-18	2
12/31/2023	10	-19	-18	-13	N/A
9/30/2023	11	-20	-21	-15	N/A
6/30/2023	11	-21	-24	-18	N/A
3/31/2023	11	-21	-25	-20	N/A
12/31/2022	11	-22	-27	-22	N/A
9/30/2022	11	-21	-24	-19	N/A
6/30/2022	11	-20	-21	-16	N/A
3/31/2022	10	-20	-19	-14	N/A
12/31/2021	10	-19	-17	-13	N/A
9/30/2021	9	-20	-16	-13	N/A
6/30/2021	8	-21	-16	-13	N/A
3/31/2021	7	-20	-17	-15	N/A
12/31/2020	6	-19	-18	-16	N/A
9/30/2020	6	-20	-20	-18	N/A
6/30/2020	6	-21	-21	-19	N/A
12/31/2019	5	-25	-22	-20	N/A
9/30/2019	5	-24	-22	-20	N/A
6/30/2019	4	-24	-22	-20	N/A
12/31/2018	4	-25	-23	-21	N/A
9/30/2018	3	-26	-24	-22	N/A
6/30/2018	3	-27	-25	-23	N/A
3/31/2018	4	-28	N/A	N/A	N/A
12/31/2017	4	-28	-26	-26	N/A
9/30/2017	5	-28	N/A	-26	N/A
6/30/2017	6	-28	N/A	-26	N/A
3/31/2017	6	-28	N/A	-25	N/A
12/31/2016	6	-29	N/A	-25	N/A
9/30/2016	6	-27	N/A	-24	N/A
6/30/2016	6	-26	N/A	-22	N/A
3/31/2016	6	-23	N/A	-19	N/A
12/31/2015	5	-20	N/A	-16	N/A
9/30/2015	5	-17	N/A	-13	N/A
6/30/2015	5	-15	N/A	-11	N/A
3/31/2015	4	-13	N/A	-9	N/A
12/31/2014	4	-10	N/A	-8	N/A
9/30/2014	4	-9	N/A	-7	N/A
6/30/2014	4	-8	N/A	-7	N/A
3/31/2014	3	-7	N/A	-6	N/A
12/31/2013	3	-7	N/A	-6	N/A
9/30/2013	3	-8	N/A	-7	N/A
6/30/2013	3	-8	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IPD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IPD今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IPD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IPDの収益 ( 39.8% ) Australian市場 ( 5.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: IPDの収益 ( 39.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IPD 3 年以内に赤字になると予測されています。

ImpediMed 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target decreased by 9.6% to AU$0.18

Consensus revenue estimates decrease by 13%

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

Consensus revenue estimates decrease by 20%

Price target decreased by 16% to AU$0.23

Recent updates

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited, Annual General Meeting, Oct 26, 2022

Price target decreased to AU$0.22

ImpediMed Limited Announces Executive Changes

Less than half of directors are independent

ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform

No longer forecast to breakeven

ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022

New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference

ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up